Jong Kyu Kwon1, Jae Heon Kim2, Hoon Choi3, In Ho Chang1, Bo Ra Park4, Soon-Sun Kwon5, Eun Sil Lee4, Gyu Yeon Choi4, Jeong Jae Lee4, Im Soon Lee4. 1. Department of Urology, Chung-Ang University Hospital, Urological Science Institute, Chung-Ang University College of Medicine, Seoul, South Korea. 2. Department of Urology, Sooncheonhyang University Hospital, Suncheonhyang University College of Medicine, Seoul, South Korea. Electronic address: piacekjh@hanmail.net. 3. Department of Urology, Korea University Hospital, Korea University College of Medicine, Ansan, South Korea. 4. Department of Obstetrics and Gynecology, Sooncheonhyang University Hospital, Sooncheonhyang University College of Medicine, Seoul, South Korea. 5. Medical Research Collaborating Center, Seoul National University Bundang Hospital, Seongnam, South Korea.
Abstract
OBJECTIVES: To characterize voiding symptoms during the peri- and post-menopausal periods and to investigate related hormonal changes. METHODS: We enrolled a total of 55 patients between February 10, 2013, and August 15, 2013, to participate in this cross-sectional study. To characterize patients' voiding symptoms, we administered voiding questionnaires, including the International Prostate Symptom Score (IPSS), Overactive Bladder Symptom Score (OABSS), and Sandvik Severity Index. Measured hormones included E2, FSH, TSH, prolactin, progesterone, and testosterone. RESULTS: In the univariate analysis, there were significant intergroup differences for all of the hormones except progesterone. Among the voiding symptoms, straining (IPSS question 1), frequency (IPSS question 2), and SUI were significantly different between the two groups (p=0.039. 0.010, and 0.017, respectively). In the multivariate analysis, frequency (IPSS question 2) and SUI were significantly different between the two groups (p=0.020 and 0.011, respectively). Among the hormones, only testosterone was marginally different between the two groups (p=0.059). CONCLUSIONS: During the transition to menopause, voiding symptoms, such as frequency, can potentially worsen in the peri-menopausal period, and SUI is more prevalent in the post-menopausal period. Additionally, testosterone may have a role in voiding changes that occur during the menopausal transition.
OBJECTIVES: To characterize voiding symptoms during the peri- and post-menopausal periods and to investigate related hormonal changes. METHODS: We enrolled a total of 55 patients between February 10, 2013, and August 15, 2013, to participate in this cross-sectional study. To characterize patients' voiding symptoms, we administered voiding questionnaires, including the International Prostate Symptom Score (IPSS), Overactive Bladder Symptom Score (OABSS), and Sandvik Severity Index. Measured hormones included E2, FSH, TSH, prolactin, progesterone, and testosterone. RESULTS: In the univariate analysis, there were significant intergroup differences for all of the hormones except progesterone. Among the voiding symptoms, straining (IPSS question 1), frequency (IPSS question 2), and SUI were significantly different between the two groups (p=0.039. 0.010, and 0.017, respectively). In the multivariate analysis, frequency (IPSS question 2) and SUI were significantly different between the two groups (p=0.020 and 0.011, respectively). Among the hormones, only testosterone was marginally different between the two groups (p=0.059). CONCLUSIONS: During the transition to menopause, voiding symptoms, such as frequency, can potentially worsen in the peri-menopausal period, and SUI is more prevalent in the post-menopausal period. Additionally, testosterone may have a role in voiding changes that occur during the menopausal transition.
Authors: John Tapper; Grace Huang; Karol M Pencina; Zhuoying Li; Stefan Arver; Anna Martling; Lennart Blomqvist; Christian Buchli; Thomas G Travison; Thomas W Storer; Shalender Bhasin; Shehzad Basaria Journal: Menopause Date: 2019-12 Impact factor: 2.953
Authors: Ariana L Smith; Liisa Hantsoo; Anna P Malykhina; Daniel W File; Rita Valentino; Alan J Wein; Mary D Sammel; C Neill Epperson Journal: Int Urogynecol J Date: 2016-03-04 Impact factor: 2.894